Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2

F. M S Gurgis, M C Åkerfeldt, B Heng, C Wong, S Adams, G J Guillemin, T G Johns, M. Chircop, Lenka Munoz

Research output: Contribution to journalArticleResearchpeer-review

Abstract

MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response. MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated. CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation. We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death. While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells. CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase. Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27. These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition. Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity. This study demonstrates how functional and mechanistic studies with appropriate selection of test compounds, combining genetic knock-down and pharmacological inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community. Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclinical pharmacology studies of all novel kinase inhibitors.

LanguageEnglish
Article number15028
Pages1-11
Number of pages11
JournalCell death discovery
Volume1
DOIs
Publication statusPublished - 2015

Fingerprint

Glioblastoma
Protein Kinase Inhibitors
Protein Kinases
Tubulin
Phosphotransferases
Cell Survival
Phosphorylation
Pharmacology
Neoplasms
G1 Phase
DNA Damage
Cell Death
Adenosine Triphosphate
Drug Therapy
Research

Bibliographical note

Copyright Cell Death Differentiation Association 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this

Gurgis, F. M S ; Åkerfeldt, M C ; Heng, B ; Wong, C ; Adams, S ; Guillemin, G J ; Johns, T G ; Chircop, M. ; Munoz, Lenka. / Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. In: Cell death discovery. 2015 ; Vol. 1. pp. 1-11.
@article{cf610e76af9940af9ae9911eac62c9d7,
title = "Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2",
abstract = "MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response. MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated. CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation. We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death. While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells. CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase. Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27. These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition. Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity. This study demonstrates how functional and mechanistic studies with appropriate selection of test compounds, combining genetic knock-down and pharmacological inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community. Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclinical pharmacology studies of all novel kinase inhibitors.",
author = "Gurgis, {F. M S} and {\AA}kerfeldt, {M C} and B Heng and C Wong and S Adams and Guillemin, {G J} and Johns, {T G} and M. Chircop and Lenka Munoz",
note = "Copyright Cell Death Differentiation Association 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2015",
doi = "10.1038/cddiscovery.2015.28",
language = "English",
volume = "1",
pages = "1--11",
journal = "Cell death discovery",
issn = "2058-7716",
publisher = "Springer, Springer Nature",

}

Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. / Gurgis, F. M S; Åkerfeldt, M C; Heng, B; Wong, C; Adams, S; Guillemin, G J; Johns, T G; Chircop, M.; Munoz, Lenka.

In: Cell death discovery, Vol. 1, 15028, 2015, p. 1-11.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2

AU - Gurgis,F. M S

AU - Åkerfeldt,M C

AU - Heng,B

AU - Wong,C

AU - Adams,S

AU - Guillemin,G J

AU - Johns,T G

AU - Chircop,M.

AU - Munoz,Lenka

N1 - Copyright Cell Death Differentiation Association 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2015

Y1 - 2015

N2 - MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response. MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated. CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation. We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death. While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells. CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase. Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27. These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition. Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity. This study demonstrates how functional and mechanistic studies with appropriate selection of test compounds, combining genetic knock-down and pharmacological inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community. Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclinical pharmacology studies of all novel kinase inhibitors.

AB - MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response. MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated. CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation. We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death. While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells. CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase. Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27. These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition. Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity. This study demonstrates how functional and mechanistic studies with appropriate selection of test compounds, combining genetic knock-down and pharmacological inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community. Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclinical pharmacology studies of all novel kinase inhibitors.

U2 - 10.1038/cddiscovery.2015.28

DO - 10.1038/cddiscovery.2015.28

M3 - Article

VL - 1

SP - 1

EP - 11

JO - Cell death discovery

T2 - Cell death discovery

JF - Cell death discovery

SN - 2058-7716

M1 - 15028

ER -